These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

6138 related articles for article (PubMed ID: 12530072)

  • 1. Augmented growth inhibition of B16-BL6 melanoma by combined treatment with a selective matrix metalloproteinase inhibitor, MMI-166, and cytotoxic agents.
    Hojo K; Maki H; Sawada TY; Maekawa R; Yoshioka T
    Anticancer Res; 2002; 22(6A):3253-9. PubMed ID: 12530072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Augmented anti-metastatic efficacy of a selective matrix metalloproteinase inhibitor, MMI-166, in combination with CPT-11.
    Maki H; Hojo K; Tanaka H; Sawada TY; Maekawa R; Yoshioka T
    Clin Exp Metastasis; 2002; 19(6):519-26. PubMed ID: 12405289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
    Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
    Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Navitoclax augments the activity of carboplatin and paclitaxel combinations in ovarian cancer cells.
    Stamelos VA; Robinson E; Redman CW; Richardson A
    Gynecol Oncol; 2013 Feb; 128(2):377-82. PubMed ID: 23168176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
    Ciardiello F; Caputo R; Bianco R; Damiano V; Pomatico G; De Placido S; Bianco AR; Tortora G
    Clin Cancer Res; 2000 May; 6(5):2053-63. PubMed ID: 10815932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies.
    Shalinsky DR; Brekken J; Zou H; Bloom LA; McDermott CD; Zook S; Varki NM; Appelt K
    Clin Cancer Res; 1999 Jul; 5(7):1905-17. PubMed ID: 10430098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Wf-536, a novel ROCK inhibitor, against metastasis of B16 melanoma.
    Nakajima M; Hayashi K; Egi Y; Katayama K; Amano Y; Uehata M; Ohtsuki M; Fujii A; Oshita K; Kataoka H; Chiba K; Goto N; Kondo T
    Cancer Chemother Pharmacol; 2003 Oct; 52(4):319-24. PubMed ID: 12783205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
    Sirotnak FM; Zakowski MF; Miller VA; Scher HI; Kris MG
    Clin Cancer Res; 2000 Dec; 6(12):4885-92. PubMed ID: 11156248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-invasive effect of MMI-166, a new selective matrix metalloproteinase inhibitor, in cervical carcinoma cell lines.
    Iwasaki M; Nishikawa A; Fujimoto T; Akutagawa N; Manase K; Endo T; Yoshida K; Maekawa R; Yoshioka T; Kudo R
    Gynecol Oncol; 2002 Apr; 85(1):103-7. PubMed ID: 11925127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Everolimus and PTK/ZK show synergistic growth inhibition in the orthotopic BL16/BL6 murine melanoma model.
    O'Reilly T; Lane HA; Wood JM; Schnell C; Littlewood-Evans A; Brueggen J; McSheehy PM
    Cancer Chemother Pharmacol; 2011 Jan; 67(1):193-200. PubMed ID: 20512579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of monotherapy and combined therapy with NSC-631570 (ukrain) on growth of low- and high-metastasizing B16 melanoma in mice.
    Skivka L; Susak Y; Trompak O; Kudryavets Y; Bezdeneznikh N; Semesiuk N; Lykhova O
    J Oncol Pharm Pract; 2011 Dec; 17(4):339-49. PubMed ID: 20817651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
    Goffin JR; Anderson IC; Supko JG; Eder JP; Shapiro GI; Lynch TJ; Shipp M; Johnson BE; Skarin AT
    Clin Cancer Res; 2005 May; 11(9):3417-24. PubMed ID: 15867243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of combination therapy with matrix metalloproteinase inhibitor MMI-166 and mitomycin C on the growth and liver metastasis of human colon cancer.
    Ohta M; Konno H; Tanaka T; Baba M; Kamiya K; Oba K; Kaneko T; Syouji T; Igarashi A; Nakamura S
    Jpn J Cancer Res; 2001 Jun; 92(6):688-95. PubMed ID: 11429059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of antitumor effects of paclitaxel (taxol) in combination with red ginseng acidic polysaccharide (RGAP).
    Shin HJ; Kim YS; Kwak YS; Song YB; Kim YS; Park JD
    Planta Med; 2004 Nov; 70(11):1033-8. PubMed ID: 15549658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-tumor angiogenic effect of a matrix metalloproteinase inhibitor MMI270.
    Nakamura ES; Koizumi K; Yamaura T; Saiki I
    Anticancer Res; 2003; 23(1A):411-7. PubMed ID: 12680241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dipyridamole augments the antitumor effects of fluorinated pyrimidines.
    Sakaguchi Y; Kusumoto T; Kusumoto H; Maehara Y; Furusawa M; Sugimachi K
    Anticancer Res; 1992; 12(1):119-21. PubMed ID: 1567156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
    Herbst RS; Giaccone G; Schiller JH; Natale RB; Miller V; Manegold C; Scagliotti G; Rosell R; Oliff I; Reeves JA; Wolf MK; Krebs AD; Averbuch SD; Ochs JS; Grous J; Fandi A; Johnson DH
    J Clin Oncol; 2004 Mar; 22(5):785-94. PubMed ID: 14990633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of RSR13 and oxygen on the cytotoxicity of cisplatin and carboplatin to EMT6 mouse mammary tumor cells in vitro and in vivo.
    Donnelly ET; Kelley M; Rockwell S
    Cancer Chemother Pharmacol; 2004 Jan; 53(1):43-50. PubMed ID: 14574460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer.
    Sirotnak FM; She Y; Lee F; Chen J; Scher HI
    Clin Cancer Res; 2002 Dec; 8(12):3870-6. PubMed ID: 12473602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically.
    Garofalo A; Naumova E; Manenti L; Ghilardi C; Ghisleni G; Caniatti M; Colombo T; Cherrington JM; Scanziani E; Nicoletti MI; Giavazzi R
    Clin Cancer Res; 2003 Aug; 9(9):3476-85. PubMed ID: 12960140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 307.